Advertisement

Journal of Neuro-Oncology

, Volume 20, Issue 2, pp 165–176 | Cite as

Drug resistance in brain tumors

  • Lynn G. Feun
  • Niramol Savaraj
  • Howard J. Landy
Article

Summary

Resistance to chemotherapy in brain tumors is complex and may involve multiple mechanisms. For commonly used drugs, such as nitrosoureas and platinum compounds, major mechanisms may involve increaded DNA repair or removal of the drug-DNA adducts. For water soluble nitrosoureas and also for platinum compounds, other mechanisms, such as alteration in drug transport, may be important. Another major mechanism may involve glutathione and glutathione-S-transferase pathways. For vinca alkaloids and epipodophyllotoxins p-glycoprotein mediated MDR appears to be the major feature in drug resistance. In addition, alteration of tubulin and topoisomerase II have been described in resistance to vinca alkaloids and epipodophyllotoxins respectively. Recently, increased multidrug resistance associated protein gene expression has been found in glioma cells and brain tumor samples; its clinical significance requires further investigation.

Key words

drug resistance brain glioma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Feun LG, Lee YY, Charnsangavej C, Yung WKA, Savaraj N, Carrasco CH, Gianturco C, Wallace S: New drugs and delivery techniques inProgress in Experimental Tumor Research Vol 29 p 131–139 (Karger, Basel 1985)Google Scholar
  2. 2.
    Grossman SA, Wharam M, Sheidler V, Zeltzman M, Zinreich J, Moynihan T, Gilbert M, Ahn H: BCNU/Cisplatin (BIC) followed by radiation in poor prognosis patients with high grade astrocytomas. Proc Am Soc Clin Oncol 11: 149, 1992Google Scholar
  3. 3.
    Rosenblum ML, Gerosa MA, Bodell WJ, Talcott RL: Tumor cell resistance inProgress in Experimental Research Vol 27, p 191–211 (Karger, Basel 1984)Google Scholar
  4. 4.
    Phillips PC: Antineoplastic resistance in brain tumors inNeurologic Clinics 9: 383–404, 1991 (May)PubMedGoogle Scholar
  5. 5.
    Eagan RT, Scott: Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 12: 38–44, 1983Google Scholar
  6. 6.
    Wheeler G: A review of studies of the mechanism of action of nitrosourea. Cancer Chemother 30: 87–119, 1976Google Scholar
  7. 7.
    Schein PS, Heal J, Green D, Woolley PV: Pharmacology of nitrosourea antitumor agents. Antibiot Chemother 23: 64–75, 1976Google Scholar
  8. 8.
    Heal TM, Fox PA, Schein PS: Effect of carbamoylation on the repair of nitrosourea-induced DNA-alkylation damage in L1210 cells. Cancer Res 39: 82–89, 1979PubMedGoogle Scholar
  9. 9.
    Erickson LC, Bradley MO, Ducore JM, Ewig RA, Kohn KW: DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas. Proc Natl Acad Sci USA 77: 467–471, 1980PubMedGoogle Scholar
  10. 10.
    Erickson LC, Laurent G, Sharkey NA, Kohn KW: DNA crosslinking and monadduct repair in nitrosourea-treated human tumor cells. Nature (Lond.) 228: 727–729, 1980Google Scholar
  11. 11.
    Bodell WJ, Rupniak NTR, Rasmussen J, Morgan WF, Rosenblum ML: Reduced level of DNA crosslinks and sister chromatid exchanges in 1,3-bis(2-chloroethyl)-l-nitrosourea resistant rat brain tumor cells. Cancer Res 44: 3763–3767, 1984PubMedGoogle Scholar
  12. 12.
    Bodell WJ, Aida T, Berger MS, Rosenblum ML: Increased repair of 0 6-alkylguanine DNA adduets in glioma derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-l-nitrosourea. Carcinogenesis 7: 879–883, 1986PubMedGoogle Scholar
  13. 13.
    Brent TP: Suppression of cross-link formation in chloroethylnitrosourea-treated DNA by an activity in extracts of human leukemic lymphoblasts. Cancer Res 44: 1887–1892, 1984PubMedGoogle Scholar
  14. 14.
    Robinson P, Harris AL, Goldsmith I, Lindahl T: Cross-linking of DNA induced by chloroethylnitrosourea is prevent by O6-methylguanine-DNA methyltransferase. Nucleic Acids Res 11: 7743–7758, 1983PubMedGoogle Scholar
  15. 15.
    Day RS, Ziolkowski CH, Scudiero DA, Meyer SA, Lubiniecki A, Girardi AJ, Galloway SM, Bynum GD. Defective repair of alkylated DNA by human tumor and SV 40-transformed human cell strains. Nature (Lond) 288: 724–727, 1980Google Scholar
  16. 16.
    Day RS, Ziolkowski CH, Scudiero DA, Meyer SA, Mattern MR: Human tumor cell strains defective in the repair of alkylation damage. Carcinogenesis (Lond) 1: 21–32, 1980Google Scholar
  17. 17.
    Scudiero DA, Meyer SA, Clatterbuck BE, Mattern MR, Ziolkowski CH, Day RS: Sensitivity of human cell strains having different abilities to repair 06-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. Cancer Res 44: 2467–2474, 1984PubMedGoogle Scholar
  18. 18.
    Yarosh DB: The role of 06-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat Res 145: 1–16, 1985PubMedGoogle Scholar
  19. 19.
    Sariban G, Kohn KW, Zlotogorski C, Laurent G, D'lncalci M, Day R, Smith BN, Kornbluth P, Erickson LC: DNA cross-linking response of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin and diaziquone. Cancer Res 47: 3988–3994, 1987PubMedGoogle Scholar
  20. 20.
    Noe AJ, Malapetsa A, McQuillan AC, Panasci LC: Bischloroethylnitrosourea (BCNU) Resistance in clinical glioma samples and human glioma cell lines may correlate with expression of 0 6-methylguanine-DNA methyltransferase (MGMT) and metallothionein (hMT) mRNA. Proc Am Soc Clin Oncol 11: 150, 1992Google Scholar
  21. 21.
    Bodell WJ, Tokuda K, Ludlum DB: Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea. Cancer Res 48: 4489–4492, 1988PubMedGoogle Scholar
  22. 22.
    Hill DL, Kirk MC, Struck RF: Microsomal metabolism of nitrosoureas. Cancer Res 35: 296–301, 1975PubMedGoogle Scholar
  23. 23.
    Hill DL, N,N’-Bis(2-chloroethyl)-N-nitrosourea, a substrate for glutathione (GSH) S-transferase. Proc Am Assoc Cancer Res 17: 52, 1976Google Scholar
  24. 24.
    Talcott RE, Levin VA: Glutathione-dependent denitrosation of BCNU: Nitrite release catalyzed by mouse liver cytosolin vitro. Drug Metab Dispos 11: 175–176, 1983PubMedGoogle Scholar
  25. 25.
    Smith MT, Evans CG, Doane-Setzar P, Castro VM, Tahir MK, Mannervik B: Denitrosation of 1,3-bis(2-chloroethyl) 1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res 49: 2621–2625, 1989PubMedGoogle Scholar
  26. 26.
    Yoshina T, Shimizu K, Ushio Y, Haykawa T, Mogami H, Sakomota: The mechanisms and overcoming of resistance in ACNU-resistant sublines of C6 and 9L rat glioma. J Neuro-Onc 5: 195–207, 1987Google Scholar
  27. 27.
    Shapiro JR, Ebrahim SAD, Mohamed AN, Pu P-Y, Shapiro WR: BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: an astrocytoma, an anaplastic astrocytoma and two glioblastoma multiforme. J Neuro-Oncol 15: 209–227, 1993Google Scholar
  28. 28.
    Freedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, Bigner DD, Schold Jr SC: Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 84: 1926–1931, 1992PubMedGoogle Scholar
  29. 29.
    Zlotogorski C, Erickson LC: Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone. Carcinogenesis (Lond) 4: 759–763, 1983Google Scholar
  30. 30.
    Zlotogorski C, Erickson LC: Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. Carcinogenesis (Lond) 5: 83–87, 1984Google Scholar
  31. 31.
    Yarosh DB, Hurst-Calderone S, Babich MA, Day RS: Inactivation of 06-methylguanine-DNA-methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by 06-methylguanine as a free base. Cancer Res 46: 1663–1668, 1986PubMedGoogle Scholar
  32. 32.
    Dolan ME, Corsico CD, Pegg AE: Exposure of Hela cells to 06-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents. Biochem Biophys Res Commun 132: 178–185, 1985PubMedGoogle Scholar
  33. 33.
    Aida T, Cheitlin RC, Bodell WJ: Inhibition of 06-alkylguanine-DNA-alkyltransferase potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis (2-chloroethyl)-1-nitrosourea. Carcinogenesis (Lond) 8: 1219–1223, 1987Google Scholar
  34. 34.
    Silber JR, Bobola MS, Evers TG, Muramoto M, Berger MS: 06-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3 bis (2-chloroethyl)-l-nitro-sourea in four medulloblastoma cell lines. Oncology Res 4: 241–248, 1992Google Scholar
  35. 35.
    Crone TM, Pegg AE: A single amino acid change in human 06-alkylguanine-DNA-alkyltransferase decreasing sensitivity to inactivation by 06-benzylguanine. Can Res 53: 4750–4753, 1993Google Scholar
  36. 36.
    Hung DT, Deen DF, Marton LJ: Differential response to 1,3-bis(2-chloroethyl)-1-nitrosourea in drug resistant and sensitive 9L rat brain tumor cells pretreated with α difluoromethylornithine and 6-thioguanine. In J Cancer 44: 658–660, 1989Google Scholar
  37. 37.
    Prado M, Rodriguez L, Chamberlain M, Silver P, Levin VA: Treatment of resistant gliomas with 1,3 bis (2-chlo-roethyl)-1-nitrosourea and α difluoromethylornithine. Neurosurgery 24: 806–809, 1989PubMedGoogle Scholar
  38. 38.
    Wong KH, Waller A, Wheeler KT: 2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells. J Neuro-Onc 11: 17–25, 1991Google Scholar
  39. 39.
    DaSilva VF, Feeley M, Raaphorst: Hyperthermia potentiation of BCNU toxicity in BCNU-resistant human glioma cells. J Neuro Onc 11: 37–31, 1991Google Scholar
  40. 40.
    Hunter KJ, Deen DF, Marton LJ: Differential response to 1,3-bis(2-chloroethyl)-l-nitrosourea in drug resistant and sensitive 9L rat brain tumor cells pretreated with α difluoromethylornithine and 6-thioguanine. Int J Cancer 44: 658–600, 1989PubMedGoogle Scholar
  41. 41.
    Levin VA, Prados MD: Treatment of recurrent gliomas and raetastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10: 766–771Google Scholar
  42. 42.
    Aid T, Bodell WJ: Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, oral cis-diamminedichloroplatinum (II) in human glial-derived cell lines. Cancer Res 47: 1361–1366, 1987PubMedGoogle Scholar
  43. 43.
    Feun LC, Wallace S, Stewart PJ, Chuang VP, Yung WKA, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young JE, Tang RA, Hardel S, Mavligit G, Fields WS: Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984PubMedGoogle Scholar
  44. 44.
    Khan AB, D'Souza BJ, Wharam MD, Champion LAA, Sinks LF, Woo SY, McCullough DC, Leventhal BG: Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 66: 2013–2020, 1982PubMedGoogle Scholar
  45. 45.
    Reed T: Platinum analogs inCancer — Principles and Practice of Oncology, pp 390–400 (Lippincott, Phil 1993)Google Scholar
  46. 46.
    Andrews PA, Mann SC, Velury Set al.: Cisplatin uptake mediated cisplatin resistance in human ovarian carcinoma cells, in Proc 5th International Symposium on Platinum and other metal coordination compounds in Cancer Chemotherapy, Padua, Italy, 1988. Boston, MA, Martinus Nijhoff, 1988, pp 248–254Google Scholar
  47. 47.
    Kraker AJ, Moore CW: Accumulation of cis-diamminedichloroplatinum (I) and platinum analog by platinum-resistant murine leukemia cellsin vitro. Cancer Res 48: 9–13, 1988PubMedGoogle Scholar
  48. 48.
    Andrews PA, Velury S, Mann SCet al.: Cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cell. Cancer Res 48: 68–73, 1989Google Scholar
  49. 49.
    Scanlon KJ, Kashani-Sabet M, Miyachi Het al.: Molecular basis of cisplatin resistance in human carcinomas, model systems. Anticancer Res 9: 1301–1312, 1989. cells. J Neuro-Onc 3: 343–348, 1986PubMedGoogle Scholar
  50. 50.
    De Graeff A, Slebos RJC, Rodenhuis S: Resistance to cis-platin and analogues; mechanism and potential clinical implications. Cancer Chemother Pharmacol 22: 325, 330Google Scholar
  51. 51.
    Mincura K, Ishiyama Y, Kowada M: Cross-resistance pattern in brain tumor cells resistant to antitumor chloroethyl-nitrosoureas. Neuro Res 14: 45–48, 1992Google Scholar
  52. 52.
    Oberc-Greenwood MA, Smith BN, Cooke C, Pepin C, Kornblith PL: Selective cytoplasmic and membrane changes induced by cisplatinum. J Neuro-Oncol 9: 191–199, 1990Google Scholar
  53. 53.
    Goodwin JW, Bottomley RH, Vaugh CB, Frank J, Pugh RP: Phase II evaluation of anguidine in central nervous system tumors: A Southwest Oncology Group study. Cancer Treat Rep 67: 285–286, 1983PubMedGoogle Scholar
  54. 54.
    Hromas R, Meyor R, Jenkins S, Barlugre B: Anguidine enhances cisplatinum-induced DNA cross-links in Chinese hamster ovary cells. Proc Assoc Cancer Res 25: 370, 1904Google Scholar
  55. 55.
    Hromas RA, Yung WKA: Anguidine potentiates cisplatinum in human brain tumor cells. J neuro-Onc 3: 343–348, 1986Google Scholar
  56. 56.
    Bergert JP, Drewinko B, Corry P, Barlogie B, Ho DH: Synergistic lethal effect of cis-dichlorodiamineplatinum and 1-B-D arabinofuranosylcytosine. Cancer Res 41: 25–30, 1981PubMedGoogle Scholar
  57. 57.
    Stewart DJ, Hugenholtz H, DaSilva V, Benolt B, Richard M, Russdi N, Marsen J, Verma S: Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas. Seminars in Onc 14: 110–115, 1987 (Suppl)Google Scholar
  58. 58.
    Kyriazis AP, Kyriazis AA, Martelo AJ: Response to single agent and combination chemotherapy to a human prostatic carcinoma grown in nude mice. Proc Am Assoc, Can Res 22: 211, 1981Google Scholar
  59. 59.
    Lai GM, Ozohs RE, Smith JF: Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 37: 4597–4600, 1988PubMedGoogle Scholar
  60. 60.
    Eder JP, Teicher BA, Holden SA, Cathcart KRS, Schnipper Le, Frei E: Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of the alkylating agents. Cancer Res 49: 595–598, 1989PubMedGoogle Scholar
  61. 61.
    Onoda JM, Nelson KK, Taylor JD, Honn KV:In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum II. Cancer Res 49: 2844–2850, 1989PubMedGoogle Scholar
  62. 62.
    Teicher BA, Herman TS, Holden SA, Epelbrum R, Liu S, Frei E: Lonidamine as a modulator of alkylating agent activityin vitro andin vivo. Cancer Res 51: 780–784, 1991PubMedGoogle Scholar
  63. 63.
    Russo A, DeGraff W, Freedman N, Mitchell JB: Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 46: 2845–2848, 1986PubMedGoogle Scholar
  64. 64.
    Herman TS, Teicher BA, Chan V: Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes. Int J Radiat Oncol Biol Physiol 16: 433–4501, 1989Google Scholar
  65. 65.
    Scanlon K, Wong H, Han H: Cyclosporin A suppresses cis-platin-induced oncogene expression in human cancer cells. Cancer Treat Res 17: 27, 1990Google Scholar
  66. 66.
    Basu A, Kozikowski AP, Soto K, Lazo JS: Cellular sensitization to cis-diammindichloroplatinum II by novel analogues of the protein kinase C activates lyngbyatoxin A. Cancer Res 51: 2511–2514, 1991PubMedGoogle Scholar
  67. 67.
    Boike GM, Averette HG, Chou TC: Enhanced cisplatin cytotoxicity and modulation of cisplatin-induced cell cycle perturbations by caffeine and pentoxifylline in gynecologic cancer cell lines. Proc Am Assoc Cancer Res 32: 408, 1991Google Scholar
  68. 68.
    Wilkhoff LJ, Dulmodge EA, Trader MW: Evaluation of trans-tetrachloro-1,2-diamminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 20: 96–99, 1987PubMedGoogle Scholar
  69. 69.
    Cabral FR, Brady RC, Schlber MJ: A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann NY Acad Sci 46: 748–756, 1986Google Scholar
  70. 70.
    Lee WC, Lin KY, Chen KN, Lai YK: Induction of HSP70 is associated with vincristine resistance in heat-shocked 9L rat brain tumor cells. Br J of Cancer 66: (4) 653–659, 1992Google Scholar
  71. 71.
    Meltzer PS, Dalton WS, Grogan: Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424, 1989PubMedGoogle Scholar
  72. 72.
    Tirelli U, Incalci M, Caretta R, Tumolo S, Franchin G, Veronesa A, Galligione E, Trovo MG, Rossi C, Grigoletto E: Etoposide (VP16-213) in malignant brain tumors: A phase II study. J Clin Oncol 2: 432–437, 1984PubMedGoogle Scholar
  73. 73.
    Sklansky BD, Mann-Kaplan RS, Reynolds Jr AF, Rosenblum ML, Walker MD: 4′-demethyl-epipodophyllotoxin-B-d-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 33: 460–467, 1974PubMedGoogle Scholar
  74. 74.
    Yang L, Row TC, Liu LF: Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res 45: 5872–5876, 1985PubMedGoogle Scholar
  75. 75.
    Lee T, Roberts D: Flux of Teniposide (VM-26) across the plasma membrane of teniposide resistant sublines of L1210 cells. Cancer Res 44: 2986–2990, 1984PubMedGoogle Scholar
  76. 76.
    Hill BT, Bellamy AS: Establishment of an etoposide-resistant human epithelial tumor cell linein vitro: Characterization of patterns of cross-resistance and drug sensitivities. In J Cancer 33: 599–608, 1984Google Scholar
  77. 77.
    Glisson B: Characterization of acquired epipodophyllotoxin-resistant Chinese hamster ovary cell lines: loss of drug-stimulated DNA cleavage activity. Cancer Res 46: 1934–1938, 1986PubMedGoogle Scholar
  78. 78.
    Pommier Y, Kerrigan D, Schwartz RE: Altered DNA topoisomerase II activity in Chinese Hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075–3081, 1986PubMedGoogle Scholar
  79. 78.
    Hellman R, Fishman H, Calogero J, Kaplan B: Etoposide (VP-16), vincristine (VCR) and procarbazine (P) with radiation therapy for the treatment of glioblastoma multiforme (GBM) final analysis. Proc Am Soc Clin Oncol 13: 181, 1994Google Scholar
  80. 79.
    Taylor S, Cowley J, Pollock TW, Eyre HJ, Jaeckle C, Hyre HE, Stephens RL: Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: A Southwest Oncology Group Trial. J Clin Oncol 9: 1476–1479Google Scholar
  81. 80.
    Feun LG, Yung WKA, Leavens MC, Burgess MA, Obbers E, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS, Bodey GP: A Phase II trial of 1,5-diaziridinyl-3,6 bis (carboethoxyamino) 1,4, benzoquinone (AZQ) NSC 182986) in recurrent primary brain tumors. J Neuro-Onc 2: 13–17, 1984Google Scholar
  82. 81.
    O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Stevens MFG: Temozolomide: a new oral cytotoxic agent with promising activity against gliomas. Proc Am Soc Clin Oncol 12: 176, 1993Google Scholar
  83. 82.
    Endicott JA, Ling V: The biochemistry of P-glycoproteinmediated multidrug resistance. Annu Rev Biochem 58: 137–171, 1989PubMedGoogle Scholar
  84. 83.
    Van der Bliek A, Borst P: Multidrug resistance. Adv Can Res 52: 165–203, 1989Google Scholar
  85. 84.
    Gerlach JH, Kartner N, Bell D, Ling V: Multidrug resistance. Cancer Survey 5: 25–46, 1986Google Scholar
  86. 85.
    Lampidis T, Savaraj N, Valet G, Fourcade A, Tapeiro H: Relationship of chemical charge of anticancer agents to drug accumulation and cytotoxicity in cardiac and tumor cells: Relevance to multidrug resistance. In: Anticancer drugs. Colloque Inserm, vol 191, pp 29–38. John Libbey Publisher, London, 1989Google Scholar
  87. 86.
    Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in themdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381–389, 1986PubMedGoogle Scholar
  88. 87.
    Raymon M, Rose E, Housman D, Gros P: Physical mapping, amplification, and overexpression of the mousemdr gene family in multidrug-resistant cells. Mol Cell Biol 10: 1642–1651, 1990PubMedGoogle Scholar
  89. 88.
    Roninson IB, Pastan J, Gottesman MM: (1991) In: Roninson IB (ed) Molecular and cell biology of multidrug resistance in tumor cell (Plenums New York) pp 91–106Google Scholar
  90. 89.
    Lincke CR, Smit JM, van der Velde-Koerts T, Borst P: Structure of the humanMDR3 and physical mapping of the humanMDR Locus. J Biol Chem 266: 5303–5310, 1991PubMedGoogle Scholar
  91. 90.
    Pastan I, Gottesman MM: Multiple-drug resistance in human cancre. New Eng J Med 316: 1388–1393, 1987PubMedGoogle Scholar
  92. 91.
    Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Parker R, Green A, Christ Net al.: Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst 81: 116–124, 1989PubMedGoogle Scholar
  93. 92.
    Cardon-Cardo C, O'Brien JP, Boccia J, Casalo D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoproteins) in human normal and tumor tissue. The J of Histo and Cytochem 38: 1277–1287, 1990Google Scholar
  94. 93.
    Matsumoto T, Tani E, Kaba K, Kochi N, Shindo H, Miyaji K: Amplification and expression of a multidrug resistance gene in human glioma cell line. J neurosurg 72: 96–101, 1990PubMedGoogle Scholar
  95. 94.
    Tishler DM, Raffel C: Development of multidrug resistance in a primitive neuroectodermal tumor cell line. J Neurosurg 76: 502–506, 1992PubMedGoogle Scholar
  96. 94a.
    Feun L, Landy H, Lu K, Li DJ, Kuo MT, Lampidis T, Green B, Savaraj N: MDRl gene expression in primary brain tumor (MBT) Proc Am Soc Clin One 8: 88, 1989Google Scholar
  97. 95.
    Nabors NW, Zehnbauer BA, Kaufman SH, Grossman SA, Zhao XL, Breem H, Long DM, Chu YW, Phillips PC, Calvin OM: MDR gene expression in human tumors. Proc Am Assoc of Cancer Res 31: 355, 1990Google Scholar
  98. 96.
    Matsumoto T, Tani E, Kaba, Shindo H, Miyaji K: Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 74: 460–466, 1991PubMedGoogle Scholar
  99. 97.
    Tisher D, Weinberg KI, Sender LS, Nolta J, Raffel C: Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of central nervous system. J Neurosurg 76: 507–512, 1992PubMedGoogle Scholar
  100. 98.
    Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT: Various methods of analysis of mdrl/P-glycoprotein in human colon cancer cell lines. J natl Cancer Inst 84: 711–714, 1992PubMedGoogle Scholar
  101. 99.
    Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–199, 1990PubMedGoogle Scholar
  102. 100.
    Trumper LH, Ho AD, Wulf G, Hunstein W: Addition of Verapamil to overcome drug resistance in multiple myeloma: Preliminary clinical observations in 10 patients. J Clin Oncol 7: 1578–1579, 1989PubMedGoogle Scholar
  103. 101.
    Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Jahman Se: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose Verapamil. J Clin Oncol 9: 17–24, 1991PubMedGoogle Scholar
  104. 102.
    Marquardt D, McCrones, Center MS: Mechanisms of multidrug resistance in HL-60 cells: Detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the reduced sequence of P-glyco-protein. Cancer Res 50: 1426–1430, 1990PubMedGoogle Scholar
  105. 103.
    Cole SPC, Bhardaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz Eu, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654, 1992PubMedGoogle Scholar
  106. 104.
    Zaman GJR, Versantwoort CHM, Smith JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EGE, Baas F, Borst P: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter in human multidrug resistant lung cancer cell line. Cancer Res 53: 1747–1750, 1993PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Lynn G. Feun
    • 1
  • Niramol Savaraj
    • 1
  • Howard J. Landy
    • 1
  1. 1.University of Miami Hospital and ClinicsMiamiUSA

Personalised recommendations